Latest News

Nivolumab/Relatlimab Yields Long-Lasting Activity in Pretreated Melanoma | Image Credit: © David A Litman -
Nivolumab/Relatlimab Yields Long-Lasting Activity in Pretreated Melanoma

March 20th 2023

Combination treatment with nivolumab and relatlimab appears to be a safe treatment option for patients with advanced melanoma who have progressed on prior anti–PD-L1 therapy.

The European Medicines Agency also validates a type 2 variation marketing authorization application for nivolumab in resected stage IIB or IIC melanoma.
FDA Accepts Supplemental BLA for Nivolumab in Stage IIB/C Melanoma

February 28th 2023

Previous research has identified a link between nutrients commonly found in a Mediterranean diet such as fiber, unsaturated fats, antioxidants, and polyphenols, and immunomodulatory/anti-tumor activities, according to a dietician from the University of Groningen.
Mediterranean Diet Correlates With Responses to Melanoma Immunotherapy

February 28th 2023

Data from the phase 2b KEYNOTE-942 trial support the FDA’s breakthrough therapy designation for adjuvant mRNA-4157-P201 plus pembrolizumab as treatment for high-risk resected melanoma.
FDA Grants Breakthrough Designation to mRNA Vaccine for Resected Melanoma

February 23rd 2023

The FDA has given fast track designation to peptide-based immunotherapy agent EVX-01 in combination with pembrolizumab for metastatic melanoma.
FDA Grants Fast Track Designation to Pembrolizumab Plus Personalized Immunotherapy for Metastatic Melanoma

January 19th 2023

Video Series
Video Interviews
OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

More News